From the INTERNATIONAL BUREAU

NOTIFICATION OF TRANSMITTAL OF COPIES OF TRANSLATION OF THE INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (CHAPTER I OR CHAPTER II OF THE PATENT COOPERATION TREATY)

(PCT Rules 44bis.3(c) and 72.2)

To:	,
SHIMIZU, Hatsushi Kantetsu Tsukuba Bldg. 6F 1-1-1, Oroshi-machi Tsuchiura-shi, Ibaraki 3000847 JAPON	RECEIVED WITH THANKS DEC. 20. 2010 SHIMIZU PATENT OFFICE

Date of mailing (day/month/year) 09 December 2010 (09.12.2010)	SHIMIZU PATENT OFFICE	
Applicant's or agent's file reference C1-A0801Y2P	IMPORTANT NOTIFICATION	
International application No. PCT/JP2009/057309	International filing date (day/month/year) 10 April 2009 (10.04.2009)	
Applicant CHUGAI SE	YAKU KABUSHIKI KAISHA et al	

1. Transmittal of the translatio	n to t	he applicant.
----------------------------------	--------	---------------

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on X patentability (Chapter I).

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter II).

Transmittal of the copy of the translation to the designated or elected Offices.

The International Bureau notifies the applicant that copies of that translation have been transmitted to the following designated or elected Offices requiring such translation:

EP

The following designated or elected Offices, having waived the requirement for such a transmittal at this time, will receive copies of that translation from the International Bureau only upon their request:

AE, AG, AL, AM, AO, AP, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EA, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OA, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

3. Reminder regarding translation into (one of) the official language(s) of the elected Office(s).

The applicant is reminded that, where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability (Chapter II).

It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned within the applicable time limit (Rule 74.1). See Volume II of the PCT Applicant's Guide for further details.

> The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Gijsbertus Beijer

Facsimile No. +41 22 338 82 70

e-mail: pt07.pct@wipo.int

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference C1-A0801Y2P	FOR FURTHER ACTION	See item 4 below	
International application No. PCT/JP2009/057309	International filing date (day/month/year) 10 April 2009 (10.04.2009)	Priority date (day/month/year) 11 April 2008 (11.04.2008)	
International Patent Classification (8t See relevant information in Form	h edition unless older edition indicated) PCT/ISA/237		
Applicant CHUGAI SEIYAKU KABUSHIKI K	AISHA	·	

1.	This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis. 1(a).			
2.	This REPORT consists of a total of 6 sheets, including this cover sheet. In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.			
3.	This re	port contains indicatio	ns relating to the following items:	
	\boxtimes	Box No. I	Basis of the report	
·		Box No. II	Priority	
		Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	
	\boxtimes	Box No. IV	Lack of unity of invention	
	X	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement	
		Box No. VI	Certain documents cited	
		Box No. VII	Certain defects in the international application	
		Box No. VIII	Certain observations on the international application	
4.	but not,		communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 licant makes an express request under Article 23(2), before the expiration of 30 months from 2).	

	Date of issuance of this report 30 November 2010 (30.11.2010)
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Gijsbertus Beijer
Facsimile No. +41 22 338 82 70	e-mail: pt07.pct@wipo.int

Form PCT/IB/373 (January 2004)

PATENT COOPERATION TREATY

TRANSLATTON From the INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) Applicant's or agent's file reference FOR FURTHER ACTION C1-A0801Y2P See paragraph 2 below International filing date (day/month/year) Priority date (day/month/year) International application No. 10.04.2009 11.04.2008 PCT/JP2009/057309 International Patent Classification (IPC) or both national classification and IPC Applicant CHUGAI SEIYAKU KABUSHIKI KAISHA This opinion contains indications relating to the following items: 1. Box No. I Basis of the opinion Box No. II Priority Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application 2. **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. 3. For further details, see notes to Form PCT/ISA/220. Date of completion of this opinion Name and mailing address of the ISA/JP Authorized officer Telephone No. Facsimile No.

International application No.
PCT/JP2009/057309

Во	k No. I	Basis of this opinion	
1.	With	n regard to the language, this opinion has been established on the basis of:	
	\boxtimes	the international application in the language in which it was filed	
		a translation of the international application into	, which is the language of a
		translation furnished for the purposes of international search (Rules 12.3(a) ar	nd 23.1(b)).
2.		This opinion has been established taking into account the rectification of Authority under Rule 91 (Rule 43bis.1(a))	·
3.		n regard to any nucleotide and/or amino acid sequence disclosed in the intion, this opinion has been established on the basis of:	memational application and necessary to the claimed
•	a.	type of material	•
İ		a sequence listing	
		table(s) related to the sequence listing	
	b.	format of material	
		on paper	
		in electronic form	
	C.	time of filing/furnishing	•
		contained in the international application as filed	
		filed together with the international application in electronic form	
		furnished subsequently to this Authority for the purposes of search	
4.		In addition, in the case that more than one version or copy of a sequence lifernished, the required statements that the information in the subsequent or acfiled or does not go beyond the application as filed, as appropriate, were furnished.	dditional copies is identical to that in the application as
5.	Addi	itional comments:	•
			•
			· .
			·
			•
			·

International application No. PCT/JP2009/057309

Вох	No. I	V Lack of unity of invention
1.	\boxtimes	In response to the invitation (Form PCT/ISA/206) to pay additional fees the applicant has, within the applicable time limit:
		paid additional fees
		paid additional fees under protest and, where applicable, the protest fee
	•	paid additional fees under protest but the applicable protest fee was not paid
		not paid additional fees
2.		This Authority found that the requirement of unity of invention is not complied with and chose not to invite the applicant to pay additional fees.
3.	This	Authority considers that the requirement of unity of invention in accordance with Rule 13.1, 13.2 and 13.3 is
		complied with
	\boxtimes	not complied with for the following reasons:
		The inventions in claims 1-50 include three
		inventions: an invention set forth in claims 1 and 9-14
		relating to an antigen-binding molecule lower in binding
		activity at pH 5.8 than at pH 7.4; an invention set forth
	•	in claims 18-23 relating to a method including having amino
		acid of an antigen-binding molecule substituted for or
		inserted into histidine; and an invention set forth in
		claims 28, 30-32 and 43-46 relating to a method of
		screening or manufacturing an antigen-binding molecule
		higher in binding activity at a first pH than at a second
		pH.
		-
		Further, a method of producing an antibody having
		reduced binding to an antigen under acid conditions by
		introducing at least a histidine residue is publicly known
		(see FEBS Lett., 1992, vol. 309, no. 1, pages 85 to 88, if
		necessary). Therefore, these three inventions do not share
		a special technical feature, and are not considered to be
		so linked as to form a single general inventive concept.
4.	Cons	sequently, this opinion has been established in respect of the following parts of the international application:
	\boxtimes	all parts
		the parts relating to claims Nos.

International application No. PCT/JP2009/057309

1.	Statement			<u> </u>
	Novelty (N)	Claims	1-50	YES
		Claims		NO NO
	Inventive step (IS)	Claims	9-27	YES
		Claims	1-8, 28-50	NO NO
	Industrial applicability (IA)	Claims	1-50	YES
		Claims		NO

Document 1: FEBS Lett., 1992, vol. 309, no. 1, pages 85 to 88

Claims 1-8 and 28-50

The invention as in claims 1-8 and 28-50 does not involve an inventive step in view of document 1 cited in the ISR.

Document 1 discloses a method of producing an antibody having reduced binding to an antigen under acid conditions by introducing histidine into a CDR region of an antibody. The antibody obtained by the method is considered to be lower in binding activity under a condition of pH 5.2 than under a condition of pH 7.8.

Accordingly, a person skilled in the art could easily produce, on the basis of the invention described in document 1, an antibody having reduced binding to an antigen under acid conditions by introducing histidine into a CDR region of an antibody, and there is no particular technical difficulty in setting the dissociation constant (KD) ratio to a desired value in such a manner that the binding activity is lower under a condition of pH 5.8 than under a condition of pH 7.4. Further, the obtained antibody is indistinguishable from the

International application No. PCT/JP2009/057309

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

antigen-binding molecule in claims 1-7. Further, a special technical feature cannot be found in applying the obtained antibody for medicinal use.

Furthermore, in the invention described in document 1, a person skilled in the art could also have screened or produced, as required when necessary, an antibody having reduced binding to an antigen under acid conditions by introducing histidine into a CDR region of an antibody.

Claims 9-27

The invention as in claims 9-27 involves an inventive step in view of document 1 cited in the ISR.

Document 1 neither describes nor suggests the method set forth in claims 9-14 and 18-23 of the present application, which improves an antigen-binding molecule. Further, a person skilled in the art could not easily conceive of the feature.